{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:48:32Z","timestamp":1789213712936,"version":"build-2803163510"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100012412","name":"Kansai Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>PV\u2010R\u2010CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) is a recently introduced regimen for untreated diffuse large B\u2010cell lymphoma (DLBCL). However, real\u2010world data comparing its efficacy and safety with those of R\u2010CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the real\u2010world efficacy and safety of PV\u2010R\u2010CHP compared with R\u2010CHOP\u2010based regimens in patients with newly diagnosed DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of patients with DLBCL who received PV\u2010R\u2010CHP or R\u2010CHOP\u2010based treatment as first\u2010line therapy at Kansai Medical University Hospital between January 2020 and August 2023. The primary endpoint was progression\u2010free survival (PFS). Other outcomes included overall survival (OS), treatment response, subgroup analyses, and adverse events. Propensity score matching was performed, and prespecified subgroup analyses were conducted in the matched cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 153 patients were included: 53 received PV\u2010R\u2010CHP and 100 received R\u2010CHOP. At 1\u2009year, both PFS and OS were significantly higher in the PV\u2010R\u2010CHP group than in the R\u2010CHOP group (PFS: 89.3% vs. 70.9%, hazard ratio [HR] 0.30 [95% confidence interval (CI): 0.12\u20130.78],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013; OS: 92.5% vs. 80.0%, HR 0.28 [95% CI: 0.08\u20130.95],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). Complete response rates were comparable between the groups (81.1% vs. 76.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.543). In propensity score\u2013matched analyses, PV\u2010R\u2010CHP was associated with improved PFS in patients with non\u2013germinal center B\u2010cell\u2013like (non\u2010GCB) DLBCL. The incidence of grade \u2265\u20093 adverse events was similar between the regimens, with lymphopenia being the most frequent toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PV\u2010R\u2010CHP may offer improved survival outcomes compared with R\u2010CHOP in newly diagnosed DLBCL, particularly in patients with non\u2010GCB, with an acceptable safety profile in a real\u2010world setting. Although longer follow\u2010up is required to confirm durability, these findings support the use of PV\u2010R\u2010CHP as a frontline treatment option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71531","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:34:04Z","timestamp":1768206844000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2010World Outcomes of Polatuzumab Vedotin Plus R\u2010\n                    <scp>CHP<\/scp>\n                    Versus R\u2010\n                    <scp>CHOP<\/scp>\n                    \u2010Based Regimens in Japanese Patients With Untreated Diffuse Large B\u2010Cell Lymphoma"],"prefix":"10.1002","volume":"15","author":[{"given":"Masaaki","family":"Hotta","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Satake","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Iwama","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokiko","family":"Hoshiyama","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Tsubokura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Fujita","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Radiology Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine Kansai Medical University  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31826aee97"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1805"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(06)70664\u20107"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation\u20102011.1.498"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(13)60313\u2010X"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(13)70122\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01994"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03418"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01366"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115304"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.03147"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201005\u20101545"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.6520"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.6.963"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/11866763_96"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102006\u201008\u2010038257"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017\u20100177"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy203"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010178623"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(11)70069\u20109"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27151"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967820.91359.ec"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290\u2010018\u20100238\u20106"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18341"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017734"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70017"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:00:02Z","timestamp":1772967602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cam4.71531"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71531","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-05-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71531"}}